Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer

被引:13
|
作者
Planas, Jacques [1 ]
Celma, Ana [1 ]
Placer, Jose [1 ]
Cuadras, Merce [1 ]
Regis, Lucas [1 ]
Gasanz, Carlos [1 ]
Trilla, Enrique [1 ]
Salvador, Carlos [1 ]
Lorente, David [1 ]
Morote, Juan [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Vall dHebron, Dept Urol, Barcelona, Spain
关键词
Androgen deprivation therapy; castration level; luteinizing hormone; prostate cancer; testosterone; SERUM TESTOSTERONE; CESSATION; AGONIST; TIME; MEN; NORMALIZATION; SUPPRESSION; WITHDRAWAL; CARCINOMA; TRENDS;
D O I
10.1080/21681805.2016.1227876
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to evaluate hormonal recovery after cessation of androgen deprivation therapy (ADT) in a group of elderly prostate cancer patients. Materials and methods: Forty patients with locally advanced or metastatic prostate cancer, with a mean age of 71.5 years [95% confidence interval (CI) 69.1-73.9], were treated with ADT for a mean duration of 74.6 months (95% CI 59.7-89.5 months). Mean follow-up time after ADT cessation was 36.5 months (95% CI 30.6-42.3 months). Serum testosterone and luteinizing hormone (LH) were determined at 6 month intervals after ADT cessation. Results: After 18 months of follow-up, all patients had recovered normal LH levels, while 38% of patients still presented castration levels of testosterone (< 50 ng/dl). A multivariate analysis was performed to find factors related to testosterone recovery (testosterone >50 ng/dl). Neither age at start of ADT nor clinical stage reached statistical significance. Only time under ADT was correlated with testosterone recovery (p = .031). Kaplan-Meier curves were obtained. Mean time for testosterone recovery was 14.5 months (95% CI 6.5-22.6 months) in patients treated with ADT for less than 60 months compared to 29.3 months (95% CI 19.6-39.1 months) in patients treated with ADT for more than 60 months (log-rank p = .029). Conclusions: Age did not correlate with testosterone recovery in a group of elderly prostate cancer patients in whom ADT was stopped. Testosterone recovery after ADT cessation was significantly correlated with time under ADT treatment. Significant implications related to economic aspects of the dosage schedule may be considered.
引用
收藏
页码:425 / 428
页数:4
相关论文
共 50 条
  • [21] The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients
    Holtfrerich, Sarah Katharina Charlotte
    Knipper, Sophie
    Purwins, Janna
    Castens, Jasmin
    Beyer, Burkhard
    Schlomm, Thorsten
    Diekhof, Esther Kristina
    PSYCHO-ONCOLOGY, 2020, 29 (08) : 1338 - 1346
  • [22] Long-term androgen deprivation therapy (ADT) with leuprorelin and quality of life in patients with advanced prostate cancer (PCa).
    Hammerer, Peter
    Manka, Lukas
    Wirth, Manfred
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [23] Domains of improvements in quality of life after testosterone recovery for high risk prostate cancer patients treated with long term androgen deprivation therapy
    Nabid, Abdenour
    Carrier, Nathalie
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Souhami, Luis
    Duclos, Marie
    Vincent, Francois
    Vass, Sylvie
    Bahoric, Boris
    Archambault, Robert
    QUALITY OF LIFE RESEARCH, 2014, 23 : 145 - 146
  • [24] Monoclonal antibodies in prophylaxis of skeletal fractures in patients with long-term androgen deprivation therapy due to prostate cancer
    Zabkowski, Tomasz
    Zielinski, Henryk
    Syrylo, Tomasz
    Wajszczuk, Marcin
    PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2011, 7 (01): : 49 - 53
  • [25] OSTEOPOROSIS IN PATIENTS WITH PROSTATE CANCER ON LONG-TERM ANDROGEN DEPRIVATION THERAPY: AN INCREASING, BUT UNDER-RECOGNIZED PROBLEM
    Brown, Janet E.
    Sherriff, Jennifer M.
    James, Nicholas D.
    BJU INTERNATIONAL, 2010, 105 (08) : 1042 - 1043
  • [26] Risk of Colorectal Cancer in Men on Long-Term Androgen Deprivation Therapy for Prostate Cancer Editorial Comment
    Walsh, Patrick C.
    JOURNAL OF UROLOGY, 2011, 186 (03): : 904 - 905
  • [27] Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy
    C Sevilla
    S L Maliski
    L Kwan
    S E Connor
    M S Litwin
    Prostate Cancer and Prostatic Diseases, 2012, 15 : 237 - 243
  • [28] Changes in the gut microbial profile during long-term androgen deprivation therapy for prostate cancer
    Wang, Lin
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (04) : 667 - 673
  • [29] Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy
    Braga-Basaria, Milena
    Dobs, Adrian S.
    Muller, Denis C.
    Carducci, Michael A.
    John, Majnu
    Egan, Josephine
    Basaria, Shehzad
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3979 - 3983
  • [30] Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy
    Sevilla, C.
    Maliski, S. L.
    Kwan, L.
    Connor, S. E.
    Litwin, M. S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (03) : 237 - 243